Scientists pinpointed the brain circuit that lets antidepressants make tinnitus worse

Millions of people take selective serotonin reuptake inhibitors, or SSRIs, to treat depression and anxiety, yet a frustrating minority come back to their doctors complaining that the ringing in their ears has gotten worse. For decades, clinicians had no mechanistic explanation. A new study published in PNAS by researchers at Anhui University and Oregon Health and Science University has now identified the specific serotonergic circuit responsible, opening a path toward treatments that could separate the antidepressant benefit from the auditory harm.

A Direct Serotonin Highway Into the Auditory Brain

The team, led by Zheng-Quan Tang at Anhui University and Laurence Trussell at OHSU, used neural tracing and viral-genetic methods in mice to identify a discrete subpopulation of serotonin-producing neurons in the dorsal raphe nucleus (DRN), a brainstem region long associated with mood regulation. These neurons project directly to the dorsal cochlear nucleus (DCN), a key auditory processing hub that is already known to show hyperactivity linked to tinnitus worsening in animals with phantom sound perception. The circuit, which the researchers label 5-HTDRN to DCN, had not been characterized before this study. When the team used optogenetics, a technique that controls neurons with pulses of light, to activate this pathway, spike activity in DCN fusiform cells shot up in a pattern consistent with tinnitus-related hyperactivity.

Why Millions of Tinnitus Patients Face a Drug Dilemma

Tinnitus affects roughly 10 to 15 percent of the global population. In the United States alone, approximately one in ten adults experiences tinnitus, translating to around 21.4 million Americans reporting symptoms in any given year. Many of those same people also live with depression or anxiety, the two most common reasons SSRIs are prescribed. The number of Americans receiving at least one antidepressant prescription grew from 32.7 million in 2013 to 37.3 million in 2018, and the trend has continued upward. The overlap between these populations is substantial, which means the circuit Tang and Trussell identified is clinically relevant for a large number of patients who currently have no good guidance on managing both conditions simultaneously.

Trussell put the clinical tension plainly: "People with tinnitus should work with their prescribing physician to find a drug regimen that gives them a balance between relief of psychiatric symptoms like depression and anxiety, while minimizing the experience of tinnitus. This study highlights the importance of clinicians recognizing and validating patient reports of medication-associated increases in tinnitus."

How Chemogenetics and Noise Exposure Confirmed the Circuit's Role

To move beyond correlation, the team turned to chemogenetics, a method that uses engineered receptors and designer molecules to switch specific neuron populations on or off without surgery or light delivery. Chemogenetic activation of the 5-HTDRN to DCN circuit was enough on its own to induce tinnitus-related behaviors in otherwise healthy mice, as measured by a modified auditory startle test. Crucially, blocking 5-HT2A receptors, the primary receptor subtype through which serotonin acts on DCN cells, largely reversed those behaviors. The researchers then ran the experiment in the other direction: noise-exposed mice with established tinnitus showed elevated serotonin levels in the DCN and heightened activity in the 5-HTDRN to DCN neurons. When the team chemogenetically inhibited this circuit in those noise-exposed animals, tinnitus-related behaviors were significantly reduced. The two-directional manipulation provides unusually strong evidence that the circuit is not merely correlated with tinnitus but is actively driving it in hyperserotonergic states.

"We've suspected that serotonin was involved in tinnitus, but we didn't really understand how. Now, using mice, we've found a specific brain circuit involving serotonin that goes straight to the auditory system, and found that it can induce tinnitus-like effects. When we turned that circuit off, we were able to ameliorate the tinnitus significantly." – Zheng-Quan Tang

Limits of a Mouse Model and What Remains Unresolved

The study was conducted entirely in mice, and the authors are careful not to overstate the translation to humans. Human auditory neuroscience is considerably more complex, and the DCN's functional role in human hearing is not as well characterized as it is in rodents. The findings also do not explain why only some SSRI users develop worsened tinnitus: individual variation in 5-HT2A receptor density, baseline serotonin tone, or prior noise exposure history likely all play a role. The researchers note that further work is needed to characterize the specific ion channels in DCN cells that serotonin activates, since those channels could themselves be drug targets, potentially allowing more precise intervention than simply blocking all 5-HT2A signaling.

A Region-Specific Drug Strategy Could Untangle the Benefit From the Harm

The most immediately actionable implication of the study is conceptual: tinnitus and depression relief may not have to come as a package deal. Trussell described the possibility of cell- or brain region-specific drugs that elevate serotonin in mood-regulating circuits while leaving the DRN-to-DCN pathway largely unaffected. Whether such specificity is pharmacologically achievable remains to be demonstrated, but the identification of a discrete, targetable circuit gives medicinal chemists a concrete starting point. In the shorter term, the study gives clinicians firmer ground for taking patient reports of SSRI-induced tinnitus seriously and for considering dose adjustments or drug switches rather than dismissing the complaints as coincidental. For the tens of millions caught between phantom sound and mood disorder, that validation alone represents meaningful progress.